Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ZYUS Life Sciences ( (TSE:ZYUS) ) just unveiled an announcement.
ZYUS Life Sciences Corporation has secured a CA$1.5 million loan from an independent director, with plans to use the funds for general working capital and advancing clinical research on its lead drug candidate, Trichomylin® softgel capsules. The company also announced amendments to a prior promissory note, extending its maturity date and issuing warrants, which could impact its financial strategy and stakeholder interests.
The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation is a Canadian-based life sciences company focused on developing and commercializing novel cannabinoid-based pharmaceutical drug candidates for pain management.
Average Trading Volume: 11,213
Technical Sentiment Signal: Sell
Current Market Cap: C$46.67M
For detailed information about ZYUS stock, go to TipRanks’ Stock Analysis page.